Safety and Efficacy of SEBORRHEAMEDIS Face Cream in Patients With Seborrheic Dermatitis
Primary Purpose
Seborrheic Dermatitis
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
SEBORRHEAMEDIS Face Cream
Sponsored by
About this trial
This is an interventional treatment trial for Seborrheic Dermatitis
Eligibility Criteria
Inclusion Criteria:
- Subject with mild (ISGA=2) to moderate (ISGA=3) facial Seborrheic dermatitis.
- Male or female aged 18 years or older.
- Subject who agrees not to use any Seborrheic Dermatitis medication during the study, except for the tested product.
- Subject is willing to sign an Informed Consent
Exclusion Criteria:
- Subject pregnant or lactating.
- Subject has a condition that requires continuous systemic or topical corticosteroid or antimycotic therapy
- Subject has a severe disease that is likely to interfere with the study conducting
- Subject has a known sensitivity to any of the ingredients contained in the tested product.
- Subject is expected to be extensively exposed to the sun during the study
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Interventional, open label, Safety/Efficacy Study
Arm Description
SEBORRHEAMEDIS Face Cream Interventional 30
Outcomes
Primary Outcome Measures
Improvement of overall ISGA. Descriptive Name of scale. Physician dermatology evaluation.
Secondary Outcome Measures
Improvement of erythema, desquamation on the target area. Physiological parameter. Physician dermatology evaluation.
Improvement of pruritus. Physiological parameter. Assessed by subject.
Number and severity of Adverse Events
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02656368
Brief Title
Safety and Efficacy of SEBORRHEAMEDIS Face Cream in Patients With Seborrheic Dermatitis
Official Title
Safety and Efficacy of SEBORRHEAMEDIS Face Cream in Patients With Seborrheic Dermatitis
Study Type
Interventional
2. Study Status
Record Verification Date
March 2015
Overall Recruitment Status
Completed
Study Start Date
January 2015 (undefined)
Primary Completion Date
December 2015 (Actual)
Study Completion Date
December 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Kamedis Ltd.
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
SEBORRHEAMEDIS Face Cream is a barrier-based, non-steroidal cream. The cream includes plant extracts The cream was designed to manage the symptoms of facial Seborrheic dermatitis symptoms such as erythema, scaling and pruritus.
Detailed Description
30 subjects will be enrolled to the study. After eligibility is confirmed, subjects will be asked to sign an Informed Consent form.
At the baseline visit, the investigator will select a target area on the face. The target area will be evaluated for erythema (redness) and desquamation (scaling) using a 5-point scale: 0 = none, 1 = minimal, 2 = mild, 3 = moderate and 4 = severe. Photography of the target area will be taken. For reference, a fixed object (such as a ruler) will be photographed in the same frame. In addition, the investigator will assess the overall facial lesions using an ISGA based on a 5-point scale. The subject will evaluate his/her pruritis over the past 24 hours, using a 5-point scale: 0 = no itching, 1 = minimal and rare itching, 2= mild itching, (subject is aware of the itching only when relaxed), 3= moderate itching (subject is often aware of the itching, which occasionally disturbs sleep), 4 = severe and constant itching.
Subjects will be instructed to use SEBORRHEAMEDIS Face Cream twice a day, morning and evening, for a consecutive period of 42 days. In addition to the baseline visit (day 0), subjects will be asked to come to the clinic for two follow-up visits at days 14 and 28 and for a final visit at day 42. A flexibility of ±2 days will be allowed. In case of an adverse event, the subject will be asked to immediately contact the clinic, and to come to an unscheduled visit if needed.
At each of the two follow-up visits and at the final visit, the investigator will evaluate the overall severity of seborrhea (ISGA) and the target area's erythema and desquamation. The subject will assess his/her pruritus over the past 24 hours.
At the final visit, the subject will also complete a product-assessment questionnaire. The questionnaire will ask several questions about satisfaction attributes, using a 5-point scale: -2 = very unsatisfied, -1 = unsatisfied, 0 = neutral, +1 = satisfied, +2 = very satisfied. Attributes will include: overall satisfaction, speed of results, ease of use, ease of spread, comfort under makeup, feel on the skin (-2 = very greasy, +2 = very moisturizing), speed of absorption, texture, color and odor
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Seborrheic Dermatitis
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
30 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Interventional, open label, Safety/Efficacy Study
Arm Type
Experimental
Arm Description
SEBORRHEAMEDIS Face Cream Interventional 30
Intervention Type
Device
Intervention Name(s)
SEBORRHEAMEDIS Face Cream
Intervention Description
SEBORRHEAMEDIS Face Cream is a barrier-based, non-steroidal cream. The cream includes plant extracts The cream was designed to manage the symptoms of facial Seborrheic dermatitis symptoms such as erythema, scaling and pruritus.
Primary Outcome Measure Information:
Title
Improvement of overall ISGA. Descriptive Name of scale. Physician dermatology evaluation.
Time Frame
Days 42
Secondary Outcome Measure Information:
Title
Improvement of erythema, desquamation on the target area. Physiological parameter. Physician dermatology evaluation.
Time Frame
Days 0, 14, 28 and 42
Title
Improvement of pruritus. Physiological parameter. Assessed by subject.
Time Frame
Days 0, 14, 28 and 42
Title
Number and severity of Adverse Events
Time Frame
Days 0, 14, 28 and 42
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subject with mild (ISGA=2) to moderate (ISGA=3) facial Seborrheic dermatitis.
Male or female aged 18 years or older.
Subject who agrees not to use any Seborrheic Dermatitis medication during the study, except for the tested product.
Subject is willing to sign an Informed Consent
Exclusion Criteria:
Subject pregnant or lactating.
Subject has a condition that requires continuous systemic or topical corticosteroid or antimycotic therapy
Subject has a severe disease that is likely to interfere with the study conducting
Subject has a known sensitivity to any of the ingredients contained in the tested product.
Subject is expected to be extensively exposed to the sun during the study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Rubén del Rio Gil, MD
Organizational Affiliation
Hospital de l'Esperit Sant
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
28458770
Citation
Barak-Shinar D, Del Rio R, Green LJ. Treatment of Seborrheic Dermatitis Using a Novel Herbal-based Cream. J Clin Aesthet Dermatol. 2017 Apr;10(4):17-23.
Results Reference
derived
Learn more about this trial
Safety and Efficacy of SEBORRHEAMEDIS Face Cream in Patients With Seborrheic Dermatitis
We'll reach out to this number within 24 hrs